Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.

Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In